Intrinsic value of Steris - STE

Previous Close

$87.93

  Intrinsic Value

$39.86

stock screener

  Rating & Target

str. sell

-55%

Previous close

$87.93

 
Intrinsic value

$39.86

 
Up/down potential

-55%

 
Rating

str. sell

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of STE stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2017), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 7.5

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2017(a)
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046
   2047

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  16.70
  2.00
  2.30
  2.57
  2.81
  3.03
  3.23
  3.41
  3.57
  3.71
  3.84
  3.95
  4.06
  4.15
  4.24
  4.31
  4.38
  4.44
  4.50
  4.55
  4.59
  4.64
  4.67
  4.70
  4.73
  4.76
  4.78
  4.81
  4.83
  4.84
  4.86
Revenue, $m
  2,613
  2,665
  2,727
  2,797
  2,875
  2,962
  3,058
  3,162
  3,275
  3,396
  3,527
  3,666
  3,815
  3,973
  4,142
  4,321
  4,510
  4,710
  4,922
  5,146
  5,383
  5,632
  5,895
  6,173
  6,465
  6,773
  7,097
  7,438
  7,797
  8,174
  8,571
Variable operating expenses, $m
 
  2,408
  2,458
  2,515
  2,580
  2,651
  2,730
  2,815
  2,907
  3,007
  3,114
  3,005
  3,127
  3,257
  3,395
  3,541
  3,696
  3,861
  4,034
  4,218
  4,412
  4,616
  4,832
  5,059
  5,299
  5,551
  5,817
  6,096
  6,390
  6,700
  7,025
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  2,385
  2,408
  2,458
  2,515
  2,580
  2,651
  2,730
  2,815
  2,907
  3,007
  3,114
  3,005
  3,127
  3,257
  3,395
  3,541
  3,696
  3,861
  4,034
  4,218
  4,412
  4,616
  4,832
  5,059
  5,299
  5,551
  5,817
  6,096
  6,390
  6,700
  7,025
Operating income, $m
  228
  258
  269
  281
  296
  311
  329
  347
  368
  390
  413
  661
  688
  717
  747
  779
  813
  850
  888
  928
  971
  1,016
  1,063
  1,113
  1,166
  1,222
  1,280
  1,342
  1,406
  1,474
  1,546
EBITDA, $m
  416
  570
  583
  598
  615
  633
  654
  676
  700
  726
  754
  784
  816
  850
  886
  924
  964
  1,007
  1,052
  1,100
  1,151
  1,204
  1,260
  1,320
  1,382
  1,448
  1,517
  1,590
  1,667
  1,748
  1,833
Interest expense (income), $m
  43
  52
  53
  55
  57
  59
  62
  64
  67
  71
  74
  78
  82
  86
  90
  95
  100
  106
  111
  118
  124
  131
  138
  145
  153
  161
  170
  179
  189
  199
  210
Earnings before tax, $m
  185
  206
  215
  226
  239
  252
  267
  283
  300
  319
  339
  584
  606
  631
  657
  684
  713
  744
  776
  811
  847
  885
  926
  968
  1,013
  1,060
  1,110
  1,162
  1,217
  1,275
  1,336
Tax expense, $m
  74
  56
  58
  61
  64
  68
  72
  76
  81
  86
  92
  158
  164
  170
  177
  185
  193
  201
  210
  219
  229
  239
  250
  261
  274
  286
  300
  314
  329
  344
  361
Net income, $m
  110
  150
  157
  165
  174
  184
  195
  207
  219
  233
  247
  426
  443
  460
  479
  499
  521
  543
  567
  592
  618
  646
  676
  707
  740
  774
  810
  848
  889
  931
  975

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  283
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  4,924
  4,734
  4,843
  4,967
  5,107
  5,262
  5,432
  5,617
  5,817
  6,033
  6,264
  6,512
  6,776
  7,058
  7,357
  7,674
  8,010
  8,366
  8,743
  9,141
  9,561
  10,004
  10,471
  10,964
  11,483
  12,029
  12,605
  13,211
  13,848
  14,519
  15,224
Adjusted assets (=assets-cash), $m
  4,641
  4,734
  4,843
  4,967
  5,107
  5,262
  5,432
  5,617
  5,817
  6,033
  6,264
  6,512
  6,776
  7,058
  7,357
  7,674
  8,010
  8,366
  8,743
  9,141
  9,561
  10,004
  10,471
  10,964
  11,483
  12,029
  12,605
  13,211
  13,848
  14,519
  15,224
Revenue / Adjusted assets
  0.563
  0.563
  0.563
  0.563
  0.563
  0.563
  0.563
  0.563
  0.563
  0.563
  0.563
  0.563
  0.563
  0.563
  0.563
  0.563
  0.563
  0.563
  0.563
  0.563
  0.563
  0.563
  0.563
  0.563
  0.563
  0.563
  0.563
  0.563
  0.563
  0.563
  0.563
Average production assets, $m
  1,914
  1,951
  1,996
  2,047
  2,105
  2,169
  2,239
  2,315
  2,397
  2,486
  2,582
  2,684
  2,793
  2,909
  3,032
  3,163
  3,301
  3,448
  3,603
  3,767
  3,940
  4,123
  4,315
  4,518
  4,732
  4,958
  5,195
  5,444
  5,707
  5,984
  6,274
Working capital, $m
  636
  360
  368
  378
  388
  400
  413
  427
  442
  459
  476
  495
  515
  536
  559
  583
  609
  636
  665
  695
  727
  760
  796
  833
  873
  914
  958
  1,004
  1,053
  1,104
  1,157
Total debt, $m
  1,478
  1,521
  1,571
  1,628
  1,692
  1,763
  1,841
  1,926
  2,017
  2,116
  2,222
  2,335
  2,457
  2,585
  2,722
  2,868
  3,022
  3,185
  3,357
  3,539
  3,732
  3,935
  4,149
  4,374
  4,612
  4,862
  5,126
  5,404
  5,696
  6,003
  6,326
Total liabilities, $m
  2,126
  2,168
  2,218
  2,275
  2,339
  2,410
  2,488
  2,573
  2,664
  2,763
  2,869
  2,982
  3,104
  3,232
  3,369
  3,515
  3,669
  3,832
  4,004
  4,186
  4,379
  4,582
  4,796
  5,021
  5,259
  5,509
  5,773
  6,051
  6,343
  6,650
  6,973
Total equity, $m
  2,799
  2,566
  2,625
  2,692
  2,768
  2,852
  2,944
  3,044
  3,153
  3,270
  3,395
  3,530
  3,673
  3,825
  3,987
  4,159
  4,342
  4,535
  4,739
  4,954
  5,182
  5,422
  5,675
  5,942
  6,224
  6,520
  6,832
  7,160
  7,506
  7,869
  8,252
Total liabilities and equity, $m
  4,925
  4,734
  4,843
  4,967
  5,107
  5,262
  5,432
  5,617
  5,817
  6,033
  6,264
  6,512
  6,777
  7,057
  7,356
  7,674
  8,011
  8,367
  8,743
  9,140
  9,561
  10,004
  10,471
  10,963
  11,483
  12,029
  12,605
  13,211
  13,849
  14,519
  15,225
Debt-to-equity ratio
  0.528
  0.590
  0.600
  0.600
  0.610
  0.620
  0.630
  0.630
  0.640
  0.650
  0.650
  0.660
  0.670
  0.680
  0.680
  0.690
  0.700
  0.700
  0.710
  0.710
  0.720
  0.730
  0.730
  0.740
  0.740
  0.750
  0.750
  0.750
  0.760
  0.760
  0.770
Adjusted equity ratio
  0.542
  0.542
  0.542
  0.542
  0.542
  0.542
  0.542
  0.542
  0.542
  0.542
  0.542
  0.542
  0.542
  0.542
  0.542
  0.542
  0.542
  0.542
  0.542
  0.542
  0.542
  0.542
  0.542
  0.542
  0.542
  0.542
  0.542
  0.542
  0.542
  0.542
  0.542

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  110
  150
  157
  165
  174
  184
  195
  207
  219
  233
  247
  426
  443
  460
  479
  499
  521
  543
  567
  592
  618
  646
  676
  707
  740
  774
  810
  848
  889
  931
  975
Depreciation, amort., depletion, $m
  188
  312
  314
  317
  319
  322
  325
  329
  333
  337
  341
  123
  128
  133
  138
  144
  151
  157
  165
  172
  180
  188
  197
  206
  216
  226
  237
  249
  261
  273
  286
Funds from operations, $m
  367
  463
  472
  482
  493
  506
  520
  535
  552
  569
  588
  549
  570
  593
  618
  644
  671
  700
  731
  764
  798
  835
  873
  913
  956
  1,000
  1,047
  1,097
  1,149
  1,204
  1,262
Change in working capital, $m
  -57
  7
  8
  9
  11
  12
  13
  14
  15
  16
  18
  19
  20
  21
  23
  24
  26
  27
  29
  30
  32
  34
  36
  37
  39
  42
  44
  46
  48
  51
  54
Cash from operations, $m
  424
  455
  463
  472
  483
  494
  507
  521
  537
  553
  571
  530
  550
  572
  595
  620
  646
  673
  703
  734
  766
  801
  837
  876
  916
  959
  1,004
  1,051
  1,101
  1,153
  1,208
Maintenance CAPEX, $m
  0
  -87
  -89
  -91
  -93
  -96
  -99
  -102
  -106
  -109
  -114
  -118
  -123
  -128
  -133
  -138
  -144
  -151
  -157
  -165
  -172
  -180
  -188
  -197
  -206
  -216
  -226
  -237
  -249
  -261
  -273
New CAPEX, $m
  -173
  -37
  -45
  -51
  -58
  -64
  -70
  -76
  -83
  -89
  -95
  -102
  -109
  -116
  -123
  -131
  -139
  -147
  -155
  -164
  -173
  -183
  -193
  -203
  -214
  -225
  -237
  -250
  -263
  -276
  -291
Cash from investing activities, $m
  -104
  -124
  -134
  -142
  -151
  -160
  -169
  -178
  -189
  -198
  -209
  -220
  -232
  -244
  -256
  -269
  -283
  -298
  -312
  -329
  -345
  -363
  -381
  -400
  -420
  -441
  -463
  -487
  -512
  -537
  -564
Free cash flow, $m
  320
  331
  329
  330
  332
  334
  338
  343
  348
  355
  362
  310
  319
  328
  339
  350
  363
  376
  390
  405
  421
  438
  456
  476
  496
  517
  540
  564
  589
  616
  644
Issuance/(repayment) of debt, $m
  -75
  43
  50
  57
  64
  71
  78
  85
  92
  99
  106
  113
  121
  129
  137
  145
  154
  163
  172
  182
  192
  203
  214
  226
  238
  250
  264
  277
  292
  307
  323
Issuance/(repurchase) of shares, $m
  -93
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  -174
  43
  50
  57
  64
  71
  78
  85
  92
  99
  106
  113
  121
  129
  137
  145
  154
  163
  172
  182
  192
  203
  214
  226
  238
  250
  264
  277
  292
  307
  323
Total cash flow (excl. dividends), $m
  127
  374
  379
  387
  396
  405
  416
  428
  440
  453
  468
  423
  440
  457
  476
  496
  517
  539
  563
  587
  614
  641
  670
  701
  734
  768
  804
  842
  881
  923
  967
Retained Cash Flow (-), $m
  224
  -50
  -59
  -67
  -76
  -84
  -92
  -100
  -109
  -117
  -125
  -134
  -143
  -153
  -162
  -172
  -182
  -193
  -204
  -216
  -228
  -240
  -253
  -267
  -281
  -296
  -312
  -328
  -346
  -364
  -382
Prev. year cash balance distribution, $m
 
  283
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  607
  320
  319
  320
  321
  324
  327
  331
  337
  342
  289
  296
  305
  314
  324
  335
  346
  358
  372
  386
  401
  417
  434
  452
  471
  492
  513
  536
  560
  585
Discount rate, %
 
  5.20
  5.46
  5.73
  6.02
  6.32
  6.64
  6.97
  7.32
  7.68
  8.07
  8.47
  8.89
  9.34
  9.81
  10.30
  10.81
  11.35
  11.92
  12.51
  13.14
  13.80
  14.49
  15.21
  15.97
  16.77
  17.61
  18.49
  19.41
  20.38
  21.40
PV of cash for distribution, $m
 
  577
  288
  270
  253
  237
  220
  204
  188
  173
  158
  118
  107
  95
  85
  74
  65
  56
  47
  40
  33
  27
  21
  17
  13
  10
  7
  5
  4
  3
  2
Current shareholders' claim on cash, %
  100
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others. Its Corporate and other segment includes the Defense and Industrial business unit.

FINANCIAL RATIOS  of  Steris (STE)

Valuation Ratios
P/E Ratio 67.9
Price to Sales 2.9
Price to Book 2.7
Price to Tangible Book
Price to Cash Flow 17.6
Price to Free Cash Flow 29.8
Growth Rates
Sales Growth Rate 16.7%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 37.3%
Cap. Spend. - 3 Yr. Gr. Rate 15%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 52.8%
Total Debt to Equity 52.8%
Interest Coverage 5
Management Effectiveness
Return On Assets 2.6%
Ret/ On Assets - 3 Yr. Avg. 4.6%
Return On Total Capital 2.5%
Ret/ On T. Cap. - 3 Yr. Avg. 4.8%
Return On Equity 3.8%
Return On Equity - 3 Yr. Avg. 7.3%
Asset Turnover 0.5
Profitability Ratios
Gross Margin 39.3%
Gross Margin - 3 Yr. Avg. 40.4%
EBITDA Margin 15.9%
EBITDA Margin - 3 Yr. Avg. 16.3%
Operating Margin 8.7%
Oper. Margin - 3 Yr. Avg. 10.2%
Pre-Tax Margin 7.1%
Pre-Tax Margin - 3 Yr. Avg. 8.7%
Net Profit Margin 4.2%
Net Profit Margin - 3 Yr. Avg. 5.5%
Effective Tax Rate 40%
Eff/ Tax Rate - 3 Yr. Avg. 36.8%
Payout Ratio 84.5%

STE stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the STE stock intrinsic value calculation we used $2613 million for the last fiscal year's total revenue generated by Steris. The default revenue input number comes from 2017 income statement of Steris. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our STE stock valuation model: a) initial revenue growth rate of 2% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 5.2%, whose default value for STE is calculated based on our internal credit rating of Steris, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Steris.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of STE stock the variable cost ratio is equal to 90.5%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for STE stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for Steris.

Corporate tax rate of 27% is the nominal tax rate for Steris. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the STE stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for STE are equal to 73.2%.

Life of production assets of 21.9 years is the average useful life of capital assets used in Steris operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for STE is equal to 13.5%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $2799 million for Steris - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 85.27 million for Steris is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Steris at the current share price and the inputted number of shares is $7.5 billion.

RELATED COMPANIES Price Int.Val. Rating
HRC Hill-Rom Holdi 83.33 37.79  str.sell
MMM 3M 239.11 131.45  sell
SYK Stryker 153.31 99.83  sell
JNJ Johnson&Johnso 142.89 147.16  hold
CNMD CONMED 50.91 15.80  str.sell
OMI Owens&Minor 19.37 34.90  hold

COMPANY NEWS

▶ STERIS Plc Value Analysis (NYSE:STE) : November 6, 2017   [Nov-06-17 01:19PM  Capital Cube]
▶ STERIS plc to Host Earnings Call   [Nov-01-17 08:00AM  ACCESSWIRE]
▶ Steris misses 2Q profit forecasts   [06:11AM  Associated Press]
▶ Should You Buy STERIS (STE) Ahead of Earnings?   [Oct-30-17 08:56AM  Zacks]
▶ ETFs with exposure to STERIS Plc : October 16, 2017   [Oct-16-17 09:59AM  Capital Cube]
▶ 5 MedTech Momentum Picks Investors Will Love   [Oct-13-17 09:27AM  Zacks]
▶ 5 MedTech Stocks for Stellar Returns in Q3   [Oct-10-17 04:59PM  Zacks]
▶ ETFs with exposure to STERIS Plc : October 3, 2017   [Oct-03-17 11:37AM  Capital Cube]
▶ When Should You Sell Steris Plc (STE)?   [Sep-29-17 03:02PM  Simply Wall St.]
▶ How Much Higher Can Medtech Climb As Investors Flee Pharma?   [Sep-14-17 05:36PM  Investor's Business Daily]
▶ Steris beats Street 1Q forecasts   [Aug-08-17 05:51PM  Associated Press]
▶ ETFs with exposure to STERIS Plc : August 4, 2017   [Aug-03-17 09:31PM  Capital Cube]
▶ ETFs with exposure to STERIS Plc : July 13, 2017   [Jul-13-17 04:37PM  Capital Cube]
▶ ETFs with exposure to STERIS Plc : June 20, 2017   [Jun-20-17 03:15PM  Capital Cube]
▶ UFP Technologies Elects Cynthia Feldmann to its Board   [Jun-09-17 11:29AM  GlobeNewswire]
▶ ETFs with exposure to STERIS Plc : June 5, 2017   [Jun-05-17 02:48PM  Capital Cube]
▶ Steris tops Street 4Q forecasts   [May-09-17 06:26AM  Associated Press]
▶ U.S. FTC Chairwoman Ramirez to step down   [Jan-13-17 11:31AM  Reuters]
▶ Is STERIS Plc (STE) A Good Stock To Buy?   [Dec-12-16 09:42AM  at Insider Monkey]
Financial statements of STE
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.